Target intelligence / Profile preview

Neuronal nicotinic acetylcholine receptor α2β2 subtype (nAChR α2β2)

Target
nAChR α2β2
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor, Cys-loop receptor superfamily
01

Overview

The neuronal nicotinic acetylcholine receptor α2β2 subtype is a pentameric ligand-gated ion channel, belonging to the Cys-loop receptor superfamily, formed by the co-assembly of α2 and β2 subunits (typically as heteropentamers)[1][2]. It mediates fast synaptic transmission by forming a cation-selective pore that opens upon binding the neurotransmitter acetylcholine, as well as exogenous ligands such as nicotine[1][2]. This subtype is predominantly expressed in certain regions of the brain and is involved in the modulation of neuronal excitability and neurotransmitter release[1][2]. It contributes to central processes including reward, cognition, and sensory processing, and has been implicated in neurodegenerative and neuropsychiatric disorders, as well as nicotine addiction[2][4]. Different subunit compositions result in diverse pharmacological and physiological properties; the α2β2 subtype, like other β2-containing nAChRs, is high-affinity for nicotine and shows unique sensitivity to other agonists and modulators[2].

Other names
Nicotinic acetylcholine receptor α2β2nAChR α2β2α2β2 neuronal nAChR
02

Mechanism of action

Allosteric ligand-gated ion channel activation (agonists bind and open cation channel); Channel desensitization (prolonged agonist exposure induces receptor desensitization); Modulation by positive/negative allosteric modulators

03

Biological functions

Signal transductionModulation of neurotransmitter releaseSynaptic transmissionRegulation of neuronal excitability
04

Disease associations

Neurodegenerative diseasePsychiatric disordersAddictionOther neurological disorders
05

Safety considerations

CNS stimulation and potential addiction liability (via nicotine and related agonists)Potential off-target effects influencing other nAChR subtypes in the nervous systemRisk of seizures at high agonist exposure
06

Interacting drugs

Nicotine

4 more in the full profile.

07

Biomarkers

Expression level of α2 or β2 subunit mRNA/protein (research context)No established clinical biomarkers specific for α2β2 subtype

Beyond the preview

Go deeper on Neuronal nicotinic acetylcholine receptor α2β2 subtype (nAChR α2β2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuronal nicotinic acetylcholine receptor α2β2 subtype (nAChR α2β2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call